| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Low Back Pain | 15 | 2022 | 53 | 2.470 |
Why?
|
| Prostatic Neoplasms | 4 | 2023 | 262 | 2.420 |
Why?
|
| Humans | 149 | 2023 | 17707 | 2.260 |
Why?
|
| Male | 100 | 2023 | 10094 | 2.050 |
Why?
|
| Plant Extracts | 9 | 2012 | 13 | 1.990 |
Why?
|
| Phytotherapy | 8 | 2012 | 12 | 1.790 |
Why?
|
| Prostatic Hyperplasia | 9 | 2011 | 24 | 1.580 |
Why?
|
| Middle Aged | 65 | 2022 | 7976 | 1.540 |
Why?
|
| Mindfulness | 3 | 2020 | 27 | 1.400 |
Why?
|
| Female | 90 | 2022 | 12729 | 1.390 |
Why?
|
| Coronary Disease | 12 | 2012 | 180 | 1.380 |
Why?
|
| Group Practice | 2 | 2020 | 24 | 1.370 |
Why?
|
| Treatment Outcome | 26 | 2022 | 1254 | 1.320 |
Why?
|
| Migraine Disorders | 5 | 2023 | 17 | 1.300 |
Why?
|
| Clinical Trials as Topic | 9 | 2011 | 131 | 1.240 |
Why?
|
| Stress, Psychological | 4 | 2020 | 140 | 1.210 |
Why?
|
| Lumbar Vertebrae | 9 | 2021 | 19 | 1.190 |
Why?
|
| Research Design | 12 | 2017 | 372 | 1.180 |
Why?
|
| Meningococcal Vaccines | 5 | 2019 | 39 | 1.170 |
Why?
|
| Aged | 44 | 2022 | 6150 | 1.150 |
Why?
|
| Acupuncture Therapy | 6 | 2013 | 35 | 1.140 |
Why?
|
| Chronic Pain | 6 | 2015 | 127 | 1.110 |
Why?
|
| Genome-Wide Association Study | 7 | 2023 | 249 | 1.100 |
Why?
|
| Chickenpox Vaccine | 6 | 2015 | 91 | 1.060 |
Why?
|
| Meditation | 4 | 2020 | 20 | 1.050 |
Why?
|
| Acute Pain | 4 | 2015 | 11 | 1.010 |
Why?
|
| Carotid Stenosis | 2 | 2022 | 8 | 1.000 |
Why?
|
| Back Pain | 11 | 2022 | 33 | 0.990 |
Why?
|
| Gout | 2 | 2016 | 2 | 0.970 |
Why?
|
| Neoplasms | 4 | 2019 | 442 | 0.970 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 5 | 2015 | 62 | 0.950 |
Why?
|
| Placebo Effect | 4 | 2012 | 7 | 0.950 |
Why?
|
| Vaccination | 12 | 2023 | 656 | 0.860 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2023 | 377 | 0.820 |
Why?
|
| Early Detection of Cancer | 3 | 2023 | 513 | 0.820 |
Why?
|
| Risk Assessment | 11 | 2020 | 1106 | 0.820 |
Why?
|
| Placebos | 4 | 2013 | 21 | 0.810 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2022 | 531 | 0.800 |
Why?
|
| Meningococcal Infections | 4 | 2019 | 17 | 0.770 |
Why?
|
| Adult | 41 | 2021 | 7658 | 0.770 |
Why?
|
| Antibodies, Bacterial | 7 | 2019 | 33 | 0.760 |
Why?
|
| Laparoscopy | 1 | 2022 | 49 | 0.760 |
Why?
|
| Whooping Cough | 4 | 2017 | 66 | 0.750 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 4 | 2017 | 88 | 0.740 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 19 | 0.740 |
Why?
|
| Androgen Antagonists | 3 | 2011 | 17 | 0.720 |
Why?
|
| Esophageal Neoplasms | 1 | 2022 | 115 | 0.720 |
Why?
|
| Quality of Life | 9 | 2022 | 521 | 0.710 |
Why?
|
| Patient Compliance | 4 | 2020 | 299 | 0.710 |
Why?
|
| Achondroplasia | 1 | 2020 | 1 | 0.710 |
Why?
|
| Kyphosis | 1 | 2020 | 1 | 0.710 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 7 | 0.700 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 6 | 2013 | 107 | 0.690 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 173 | 0.680 |
Why?
|
| California | 19 | 2021 | 2327 | 0.670 |
Why?
|
| Uric Acid | 2 | 2016 | 9 | 0.640 |
Why?
|
| Vaccines, Conjugate | 5 | 2019 | 59 | 0.630 |
Why?
|
| Retrospective Studies | 14 | 2022 | 2471 | 0.630 |
Why?
|
| Prospective Studies | 16 | 2022 | 1287 | 0.630 |
Why?
|
| Prostate-Specific Antigen | 4 | 2023 | 75 | 0.620 |
Why?
|
| Double-Blind Method | 11 | 2019 | 160 | 0.610 |
Why?
|
| Community Health Services | 1 | 2019 | 80 | 0.610 |
Why?
|
| Glucocorticoids | 2 | 2015 | 23 | 0.600 |
Why?
|
| Continental Population Groups | 1 | 2020 | 301 | 0.600 |
Why?
|
| Seizures, Febrile | 3 | 2015 | 42 | 0.590 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 327 | 0.570 |
Why?
|
| Patient Selection | 7 | 2020 | 190 | 0.570 |
Why?
|
| Serenoa | 5 | 2009 | 5 | 0.570 |
Why?
|
| Caregivers | 1 | 2019 | 128 | 0.570 |
Why?
|
| Feasibility Studies | 7 | 2020 | 111 | 0.570 |
Why?
|
| Analgesics, Opioid | 4 | 2021 | 243 | 0.560 |
Why?
|
| Risk Factors | 21 | 2022 | 3367 | 0.550 |
Why?
|
| Surveys and Questionnaires | 13 | 2020 | 1322 | 0.550 |
Why?
|
| Professional Role | 1 | 2016 | 10 | 0.530 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 7 | 0.530 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.520 |
Why?
|
| Primary Health Care | 8 | 2021 | 756 | 0.520 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2016 | 16 | 0.520 |
Why?
|
| Infant | 12 | 2020 | 1199 | 0.520 |
Why?
|
| Child | 15 | 2020 | 2481 | 0.520 |
Why?
|
| Spinal Stenosis | 4 | 2019 | 4 | 0.510 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 212 | 0.510 |
Why?
|
| Pharmacists | 1 | 2016 | 50 | 0.510 |
Why?
|
| WT1 Proteins | 1 | 2015 | 1 | 0.510 |
Why?
|
| ADAM Proteins | 1 | 2015 | 1 | 0.510 |
Why?
|
| Hernia, Inguinal | 1 | 2015 | 3 | 0.510 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 6 | 0.510 |
Why?
|
| Child, Preschool | 11 | 2020 | 1417 | 0.510 |
Why?
|
| Triglycerides | 4 | 2000 | 89 | 0.510 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 9 | 0.510 |
Why?
|
| Vaccines | 4 | 2011 | 218 | 0.500 |
Why?
|
| United States | 20 | 2021 | 3914 | 0.500 |
Why?
|
| Disability Evaluation | 9 | 2018 | 46 | 0.490 |
Why?
|
| Cohort Studies | 16 | 2021 | 2589 | 0.490 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2015 | 2 | 0.490 |
Why?
|
| Prednisone | 1 | 2015 | 6 | 0.490 |
Why?
|
| Radiculopathy | 1 | 2015 | 5 | 0.480 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 137 | 0.460 |
Why?
|
| Stroke | 4 | 2022 | 316 | 0.460 |
Why?
|
| Time Factors | 11 | 2019 | 1095 | 0.450 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2020 | 23 | 0.450 |
Why?
|
| Gout Suppressants | 1 | 2014 | 2 | 0.450 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 4 | 0.440 |
Why?
|
| Aged, 80 and over | 14 | 2022 | 1927 | 0.440 |
Why?
|
| Incidence | 11 | 2022 | 1269 | 0.440 |
Why?
|
| Disabled Persons | 5 | 2018 | 35 | 0.430 |
Why?
|
| Follow-Up Studies | 11 | 2017 | 1218 | 0.430 |
Why?
|
| Asymptomatic Diseases | 3 | 2022 | 29 | 0.430 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2012 | 99 | 0.420 |
Why?
|
| Lidocaine | 3 | 2019 | 5 | 0.420 |
Why?
|
| Pilot Projects | 4 | 2019 | 215 | 0.410 |
Why?
|
| Practice Guidelines as Topic | 3 | 2011 | 314 | 0.410 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2012 | 13 | 0.400 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 448 | 0.400 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2012 | 4 | 0.400 |
Why?
|
| Alcoholism | 7 | 2000 | 332 | 0.400 |
Why?
|
| Sciatica | 1 | 2012 | 2 | 0.400 |
Why?
|
| Hypertriglyceridemia | 4 | 1998 | 13 | 0.390 |
Why?
|
| Cause of Death | 1 | 2012 | 181 | 0.370 |
Why?
|
| Mind-Body Therapies | 1 | 2011 | 9 | 0.370 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2012 | 23 | 0.370 |
Why?
|
| Adolescent | 16 | 2021 | 3671 | 0.370 |
Why?
|
| Immunization | 4 | 2023 | 70 | 0.370 |
Why?
|
| Spinal Diseases | 2 | 2021 | 2 | 0.360 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2011 | 21 | 0.350 |
Why?
|
| Glucosamine | 1 | 2010 | 3 | 0.350 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2010 | 1 | 0.350 |
Why?
|
| Osteoarthritis | 1 | 2010 | 15 | 0.350 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 20 | 0.340 |
Why?
|
| Ethics, Medical | 3 | 1998 | 5 | 0.340 |
Why?
|
| Guideline Adherence | 2 | 2016 | 155 | 0.340 |
Why?
|
| HIV Infections | 11 | 1997 | 704 | 0.340 |
Why?
|
| Osteoarthritis, Knee | 3 | 2016 | 11 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 324 | 0.340 |
Why?
|
| Disease Outbreaks | 3 | 2017 | 36 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2009 | 381 | 0.330 |
Why?
|
| Young Adult | 12 | 2023 | 2450 | 0.320 |
Why?
|
| Mass Screening | 7 | 2020 | 667 | 0.320 |
Why?
|
| Internship and Residency | 3 | 2006 | 46 | 0.320 |
Why?
|
| Genetic Loci | 2 | 2021 | 55 | 0.320 |
Why?
|
| Anesthetics, Local | 4 | 2019 | 6 | 0.320 |
Why?
|
| Databases, Factual | 4 | 2020 | 311 | 0.310 |
Why?
|
| Hypercholesterolemia | 3 | 1998 | 32 | 0.310 |
Why?
|
| Infant, Premature | 2 | 2010 | 62 | 0.300 |
Why?
|
| Antibody Formation | 1 | 2018 | 7 | 0.300 |
Why?
|
| Sexual Behavior | 7 | 1997 | 123 | 0.300 |
Why?
|
| Lovastatin | 1 | 2008 | 7 | 0.290 |
Why?
|
| Liver | 1 | 2008 | 33 | 0.290 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 45 | 0.290 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 68 | 0.290 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 10 | 0.290 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 717 | 0.290 |
Why?
|
| Massage | 1 | 2007 | 18 | 0.290 |
Why?
|
| Thrombolytic Therapy | 3 | 2017 | 20 | 0.280 |
Why?
|
| Fatigue | 1 | 2007 | 34 | 0.280 |
Why?
|
| Papillomavirus Vaccines | 2 | 2023 | 113 | 0.280 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 377 | 0.280 |
Why?
|
| Measles Vaccine | 1 | 2017 | 17 | 0.270 |
Why?
|
| Specialty Boards | 2 | 1998 | 2 | 0.270 |
Why?
|
| Antibodies, Viral | 4 | 2012 | 65 | 0.270 |
Why?
|
| Fever | 1 | 2017 | 55 | 0.270 |
Why?
|
| Educational Measurement | 2 | 1998 | 18 | 0.270 |
Why?
|
| Cluster Analysis | 1 | 2017 | 90 | 0.270 |
Why?
|
| Urologic Diseases | 1 | 2006 | 7 | 0.260 |
Why?
|
| Registries | 5 | 2017 | 470 | 0.260 |
Why?
|
| Blood Bactericidal Activity | 4 | 2019 | 10 | 0.260 |
Why?
|
| HIV Seropositivity | 3 | 2000 | 31 | 0.260 |
Why?
|
| Diphtheria | 1 | 2016 | 13 | 0.250 |
Why?
|
| Tetanus | 1 | 2016 | 17 | 0.250 |
Why?
|
| Bayes Theorem | 3 | 2011 | 72 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 172 | 0.250 |
Why?
|
| Ginkgo biloba | 1 | 2005 | 1 | 0.250 |
Why?
|
| Plant Preparations | 1 | 2005 | 5 | 0.250 |
Why?
|
| Life Style | 2 | 2006 | 332 | 0.250 |
Why?
|
| Single-Blind Method | 3 | 2019 | 45 | 0.250 |
Why?
|
| Age Factors | 5 | 2019 | 918 | 0.240 |
Why?
|
| Hypertension | 2 | 2012 | 498 | 0.240 |
Why?
|
| Hemorrhage | 1 | 2005 | 62 | 0.240 |
Why?
|
| Patient Advocacy | 2 | 1998 | 13 | 0.240 |
Why?
|
| Meta-Analysis as Topic | 3 | 2021 | 32 | 0.240 |
Why?
|
| Telemedicine | 2 | 2019 | 185 | 0.240 |
Why?
|
| Outcome Assessment (Health Care) | 5 | 2016 | 227 | 0.230 |
Why?
|
| Yoga | 2 | 2020 | 26 | 0.230 |
Why?
|
| Vaccines, Combined | 5 | 2015 | 80 | 0.230 |
Why?
|
| Health Maintenance Organizations | 2 | 2010 | 414 | 0.230 |
Why?
|
| Infant, Newborn | 4 | 2020 | 857 | 0.220 |
Why?
|
| Myocardial Infarction | 4 | 2006 | 234 | 0.220 |
Why?
|
| Risk | 5 | 2012 | 517 | 0.220 |
Why?
|
| Attitude to Health | 4 | 2013 | 159 | 0.220 |
Why?
|
| DNA Glycosylases | 1 | 2023 | 5 | 0.210 |
Why?
|
| Pertussis Vaccine | 1 | 2013 | 14 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 75 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2003 | 87 | 0.210 |
Why?
|
| Drug Prescriptions | 4 | 2021 | 151 | 0.210 |
Why?
|
| Osteoarthritis, Hip | 2 | 2016 | 8 | 0.210 |
Why?
|
| Risk-Taking | 5 | 2000 | 107 | 0.210 |
Why?
|
| Endarterectomy, Carotid | 1 | 2022 | 6 | 0.200 |
Why?
|
| Neisseria meningitidis | 3 | 2019 | 10 | 0.200 |
Why?
|
| Ischemic Attack, Transient | 1 | 2022 | 27 | 0.200 |
Why?
|
| Brain Ischemia | 1 | 2022 | 37 | 0.200 |
Why?
|
| Esophagectomy | 1 | 2022 | 2 | 0.200 |
Why?
|
| Thoracoscopy | 1 | 2022 | 3 | 0.200 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2022 | 6 | 0.200 |
Why?
|
| Immunization, Secondary | 4 | 2019 | 57 | 0.190 |
Why?
|
| Patient Satisfaction | 5 | 2013 | 204 | 0.190 |
Why?
|
| Urban Population | 2 | 2000 | 114 | 0.190 |
Why?
|
| Animals | 2 | 2018 | 262 | 0.190 |
Why?
|
| Prostate | 3 | 2006 | 28 | 0.190 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2012 | 95 | 0.190 |
Why?
|
| Zygapophyseal Joint | 1 | 2021 | 1 | 0.190 |
Why?
|
| Diet | 1 | 2003 | 367 | 0.180 |
Why?
|
| Genital Diseases, Female | 1 | 2021 | 9 | 0.180 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 139 | 0.180 |
Why?
|
| Immunization Schedule | 5 | 2017 | 122 | 0.180 |
Why?
|
| Length of Stay | 1 | 2022 | 182 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2022 | 103 | 0.180 |
Why?
|
| Cholesterol, LDL | 2 | 2000 | 119 | 0.180 |
Why?
|
| Injections, Epidural | 5 | 2022 | 6 | 0.180 |
Why?
|
| Cervical Vertebrae | 1 | 2020 | 1 | 0.180 |
Why?
|
| Foramen Magnum | 1 | 2020 | 1 | 0.180 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 2 | 0.180 |
Why?
|
| Orthopedics | 1 | 2020 | 4 | 0.180 |
Why?
|
| Internal Medicine | 2 | 2006 | 20 | 0.180 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 6 | 0.180 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 7 | 0.170 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 397 | 0.170 |
Why?
|
| Benchmarking | 1 | 2020 | 40 | 0.170 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 44 | 0.170 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 49 | 0.170 |
Why?
|
| Brain | 1 | 2020 | 47 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 379 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2006 | 95 | 0.170 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 8 | 0.170 |
Why?
|
| Chronic Disease | 6 | 2014 | 416 | 0.170 |
Why?
|
| Prognosis | 4 | 2015 | 613 | 0.170 |
Why?
|
| Pain | 4 | 2021 | 79 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2017 | 1117 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2009 | 20 | 0.160 |
Why?
|
| Research Subjects | 3 | 1998 | 6 | 0.160 |
Why?
|
| Urination Disorders | 2 | 2011 | 10 | 0.160 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2019 | 12 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2012 | 245 | 0.160 |
Why?
|
| Common Cold | 1 | 1999 | 2 | 0.160 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 3 | 0.160 |
Why?
|
| Random Allocation | 1 | 1998 | 37 | 0.160 |
Why?
|
| Serogroup | 2 | 2019 | 10 | 0.160 |
Why?
|
| Bundle-Branch Block | 1 | 1998 | 5 | 0.160 |
Why?
|
| Logistic Models | 5 | 2013 | 918 | 0.160 |
Why?
|
| Clinical Medicine | 1 | 1998 | 3 | 0.150 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2019 | 61 | 0.150 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 203 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 79 | 0.150 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 59 | 0.150 |
Why?
|
| Fibromatosis, Plantar | 1 | 2018 | 1 | 0.150 |
Why?
|
| Fasciitis, Plantar | 1 | 2018 | 1 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 1 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 596 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2018 | 4 | 0.150 |
Why?
|
| Apnea | 1 | 2008 | 3 | 0.150 |
Why?
|
| Steroids | 2 | 2022 | 14 | 0.150 |
Why?
|
| Rotator Cuff Injuries | 1 | 2017 | 2 | 0.150 |
Why?
|
| Substance Abuse Treatment Centers | 3 | 1997 | 74 | 0.150 |
Why?
|
| San Francisco | 8 | 2006 | 64 | 0.150 |
Why?
|
| Herpes Zoster | 1 | 2019 | 82 | 0.150 |
Why?
|
| Ankle Injuries | 1 | 2017 | 1 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 1998 | 145 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2010 | 82 | 0.140 |
Why?
|
| Early Diagnosis | 2 | 2015 | 38 | 0.140 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2008 | 41 | 0.140 |
Why?
|
| Episode of Care | 1 | 2017 | 11 | 0.140 |
Why?
|
| Haemophilus Infections | 1 | 2017 | 5 | 0.140 |
Why?
|
| Vaccine Potency | 1 | 2017 | 4 | 0.140 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2017 | 1 | 0.140 |
Why?
|
| Tendinopathy | 1 | 2017 | 1 | 0.140 |
Why?
|
| Crowdsourcing | 1 | 2017 | 3 | 0.140 |
Why?
|
| Haemophilus Vaccines | 1 | 2017 | 17 | 0.140 |
Why?
|
| Clinical Protocols | 3 | 2012 | 42 | 0.140 |
Why?
|
| Sex Factors | 4 | 2021 | 639 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2017 | 16 | 0.140 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 44 | 0.130 |
Why?
|
| Chickenpox | 1 | 2007 | 35 | 0.130 |
Why?
|
| Prevalence | 5 | 2020 | 882 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 355 | 0.130 |
Why?
|
| Coronary Artery Disease | 1 | 1998 | 133 | 0.130 |
Why?
|
| Knee Injuries | 1 | 2016 | 1 | 0.130 |
Why?
|
| Streptokinase | 2 | 1995 | 2 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2016 | 3 | 0.130 |
Why?
|
| Sick Leave | 2 | 2016 | 8 | 0.130 |
Why?
|
| Injury Severity Score | 1 | 2016 | 10 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 1 | 2017 | 66 | 0.130 |
Why?
|
| Occupational Diseases | 1 | 2016 | 41 | 0.130 |
Why?
|
| Curriculum | 2 | 2007 | 36 | 0.130 |
Why?
|
| Administration, Oral | 2 | 2015 | 84 | 0.130 |
Why?
|
| ADAMTS Proteins | 1 | 2015 | 1 | 0.130 |
Why?
|
| Confidence Intervals | 5 | 2016 | 237 | 0.130 |
Why?
|
| Mice | 1 | 2015 | 69 | 0.130 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 115 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 710 | 0.120 |
Why?
|
| Health Services | 1 | 2016 | 114 | 0.120 |
Why?
|
| Recovery of Function | 2 | 2012 | 27 | 0.120 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2014 | 1 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 34 | 0.120 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 1322 | 0.120 |
Why?
|
| Acute Disease | 1 | 2015 | 141 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 54 | 0.120 |
Why?
|
| Quality of Health Care | 1 | 2016 | 276 | 0.110 |
Why?
|
| Allopurinol | 1 | 2014 | 2 | 0.110 |
Why?
|
| AIDS Serodiagnosis | 4 | 1994 | 10 | 0.110 |
Why?
|
| Tetanus Toxoid | 2 | 2018 | 11 | 0.110 |
Why?
|
| Behavior Therapy | 2 | 2006 | 144 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2014 | 53 | 0.110 |
Why?
|
| Algorithms | 1 | 2015 | 237 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2014 | 67 | 0.110 |
Why?
|
| Aging | 1 | 2014 | 163 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 60 | 0.110 |
Why?
|
| Patient Admission | 3 | 2000 | 71 | 0.110 |
Why?
|
| Anonymous Testing | 1 | 1993 | 1 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 49 | 0.100 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2012 | 5 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 211 | 0.100 |
Why?
|
| Syncope | 1 | 2012 | 12 | 0.100 |
Why?
|
| Confidentiality | 1 | 1993 | 25 | 0.100 |
Why?
|
| Health Education | 2 | 2007 | 110 | 0.100 |
Why?
|
| Mothers | 2 | 2011 | 106 | 0.100 |
Why?
|
| Propanolamines | 1 | 2012 | 3 | 0.100 |
Why?
|
| United States Public Health Service | 2 | 2007 | 4 | 0.100 |
Why?
|
| Breast Milk Expression | 1 | 2011 | 1 | 0.090 |
Why?
|
| Recurrence | 1 | 2012 | 189 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 107 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 43 | 0.090 |
Why?
|
| Urinary Incontinence, Urge | 1 | 2011 | 3 | 0.090 |
Why?
|
| Affect | 1 | 2011 | 25 | 0.090 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2011 | 2 | 0.090 |
Why?
|
| Government Regulation | 1 | 2011 | 8 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2012 | 301 | 0.090 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 18 | 0.090 |
Why?
|
| Financing, Government | 1 | 2011 | 27 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 123 | 0.090 |
Why?
|
| Health Surveys | 1 | 2011 | 260 | 0.090 |
Why?
|
| Safety | 1 | 2011 | 41 | 0.090 |
Why?
|
| ROC Curve | 3 | 2000 | 77 | 0.090 |
Why?
|
| Urodynamics | 2 | 2011 | 4 | 0.090 |
Why?
|
| Vaccines, Acellular | 2 | 2012 | 11 | 0.090 |
Why?
|
| Enalapril | 1 | 2010 | 8 | 0.090 |
Why?
|
| Models, Biological | 1 | 2010 | 30 | 0.090 |
Why?
|
| Morbidity | 1 | 2010 | 59 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2011 | 166 | 0.090 |
Why?
|
| Hospitalization | 2 | 2012 | 805 | 0.080 |
Why?
|
| Prunus africana | 1 | 2009 | 1 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2015 | 694 | 0.080 |
Why?
|
| Patient Preference | 1 | 2010 | 48 | 0.080 |
Why?
|
| Chromosome Mapping | 2 | 2021 | 18 | 0.080 |
Why?
|
| Pamphlets | 1 | 2009 | 7 | 0.080 |
Why?
|
| Cholesterol | 1 | 1990 | 106 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2011 | 137 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2020 | 7 | 0.080 |
Why?
|
| Rabbits | 1 | 2018 | 6 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2018 | 4 | 0.070 |
Why?
|
| Sexuality | 1 | 2008 | 11 | 0.070 |
Why?
|
| Chondroitin Sulfates | 1 | 2007 | 1 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2008 | 6 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2008 | 13 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 371 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 22 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2008 | 23 | 0.070 |
Why?
|
| Data Collection | 3 | 2013 | 252 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 296 | 0.070 |
Why?
|
| Comorbidity | 3 | 2016 | 590 | 0.070 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2018 | 50 | 0.070 |
Why?
|
| Psychometrics | 1 | 2007 | 122 | 0.070 |
Why?
|
| Social Values | 1 | 2007 | 14 | 0.070 |
Why?
|
| Family Health | 1 | 2017 | 44 | 0.070 |
Why?
|
| Forecasting | 1 | 2007 | 74 | 0.070 |
Why?
|
| Type A Personality | 1 | 2006 | 4 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2012 | 670 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 13 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2007 | 90 | 0.070 |
Why?
|
| Medical Records | 2 | 2009 | 97 | 0.060 |
Why?
|
| Propensity Score | 2 | 2018 | 85 | 0.060 |
Why?
|
| Statistics as Topic | 2 | 1998 | 62 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2006 | 35 | 0.060 |
Why?
|
| Pregnancy | 2 | 2022 | 1535 | 0.060 |
Why?
|
| Bias | 2 | 1998 | 103 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2005 | 8 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 387 | 0.060 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 626 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 211 | 0.060 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 5 | 0.060 |
Why?
|
| Heart Failure | 1 | 2010 | 398 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 47 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 4 | 2012 | 243 | 0.060 |
Why?
|
| Gestational Age | 2 | 2011 | 116 | 0.060 |
Why?
|
| Voluntary Programs | 3 | 1994 | 3 | 0.060 |
Why?
|
| Drug Costs | 2 | 2012 | 34 | 0.060 |
Why?
|
| Linear Models | 2 | 2009 | 229 | 0.060 |
Why?
|
| Disease Progression | 2 | 2015 | 266 | 0.060 |
Why?
|
| Food-Drug Interactions | 1 | 2003 | 1 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 2015 | 74 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2004 | 63 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2003 | 61 | 0.050 |
Why?
|
| Immunologic Memory | 1 | 2013 | 3 | 0.050 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2023 | 3 | 0.050 |
Why?
|
| DNA Repair Enzymes | 1 | 2023 | 6 | 0.050 |
Why?
|
| Hospitals, Veterans | 2 | 2006 | 32 | 0.050 |
Why?
|
| Quantitative Trait Loci | 1 | 2023 | 38 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2005 | 300 | 0.050 |
Why?
|
| Transcriptome | 1 | 2023 | 25 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2003 | 93 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2023 | 39 | 0.050 |
Why?
|
| Educational Status | 1 | 2003 | 198 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2003 | 108 | 0.050 |
Why?
|
| Bordetella pertussis | 1 | 2012 | 4 | 0.050 |
Why?
|
| Self Care | 1 | 2003 | 164 | 0.050 |
Why?
|
| Lumbosacral Region | 1 | 2021 | 2 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 33 | 0.050 |
Why?
|
| Pelvic Infection | 1 | 2021 | 1 | 0.050 |
Why?
|
| Pelvic Pain | 1 | 2021 | 3 | 0.050 |
Why?
|
| Uterine Hemorrhage | 1 | 2021 | 9 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 1993 | 80 | 0.050 |
Why?
|
| Hispanic Americans | 2 | 2021 | 397 | 0.050 |
Why?
|
| Insurance, Health | 2 | 2009 | 175 | 0.050 |
Why?
|
| European Continental Ancestry Group | 2 | 2021 | 523 | 0.040 |
Why?
|
| Cisapride | 1 | 2000 | 1 | 0.040 |
Why?
|
| Dyspepsia | 1 | 2000 | 5 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2000 | 3 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2020 | 6 | 0.040 |
Why?
|
| Angiography | 1 | 2020 | 12 | 0.040 |
Why?
|
| Helicobacter pylori | 1 | 2000 | 24 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 3 | 0.040 |
Why?
|
| African Americans | 2 | 2021 | 465 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 128 | 0.040 |
Why?
|
| Asian Americans | 1 | 2021 | 175 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2010 | 18 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2010 | 5 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 4 | 0.040 |
Why?
|
| Monocytes | 1 | 2010 | 5 | 0.040 |
Why?
|
| Demography | 2 | 2017 | 100 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2000 | 81 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2010 | 189 | 0.040 |
Why?
|
| Age Distribution | 1 | 2010 | 246 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 286 | 0.040 |
Why?
|
| Ethnic Groups | 2 | 1993 | 474 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 26 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 1999 | 18 | 0.040 |
Why?
|
| Philosophy, Medical | 1 | 1998 | 1 | 0.040 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1998 | 1 | 0.040 |
Why?
|
| Informed Consent | 1 | 1998 | 20 | 0.040 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 1999 | 86 | 0.040 |
Why?
|
| Chest Pain | 1 | 1998 | 15 | 0.040 |
Why?
|
| Physicians, Women | 1 | 1998 | 10 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2020 | 189 | 0.040 |
Why?
|
| Prejudice | 1 | 1998 | 23 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 1998 | 18 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 1999 | 48 | 0.040 |
Why?
|
| False Positive Reactions | 2 | 2015 | 26 | 0.040 |
Why?
|
| Spouses | 1 | 1998 | 10 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Athletic Injuries | 1 | 2018 | 3 | 0.040 |
Why?
|
| National Health Programs | 1 | 1998 | 10 | 0.040 |
Why?
|
| Area Under Curve | 1 | 1998 | 34 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 48 | 0.040 |
Why?
|
| HIV Antibodies | 2 | 1995 | 4 | 0.040 |
Why?
|
| Actinin | 1 | 2017 | 1 | 0.040 |
Why?
|
| Sprains and Strains | 1 | 2017 | 1 | 0.040 |
Why?
|
| Genotype | 1 | 2018 | 227 | 0.040 |
Why?
|
| Psychological Tests | 1 | 1997 | 11 | 0.040 |
Why?
|
| Haemophilus influenzae type b | 1 | 2017 | 2 | 0.040 |
Why?
|
| Machine Learning | 1 | 2018 | 47 | 0.040 |
Why?
|
| Bacterial Capsules | 1 | 2017 | 5 | 0.040 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2017 | 1 | 0.030 |
Why?
|
| Achilles Tendon | 1 | 2017 | 2 | 0.030 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2017 | 12 | 0.030 |
Why?
|
| Twins | 1 | 2007 | 11 | 0.030 |
Why?
|
| Diseases in Twins | 1 | 2007 | 15 | 0.030 |
Why?
|
| Siblings | 1 | 2007 | 12 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 151 | 0.030 |
Why?
|
| Sex Education | 1 | 1997 | 7 | 0.030 |
Why?
|
| Workers' Compensation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pain Management | 1 | 2017 | 57 | 0.030 |
Why?
|
| Occupational Health | 1 | 2016 | 17 | 0.030 |
Why?
|
| Veterans | 1 | 1998 | 137 | 0.030 |
Why?
|
| Health Facilities | 1 | 2016 | 16 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 1998 | 151 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 561 | 0.030 |
Why?
|
| Family Planning Services | 2 | 1993 | 19 | 0.030 |
Why?
|
| Aspirin | 1 | 1996 | 63 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 252 | 0.030 |
Why?
|
| Office Visits | 1 | 2016 | 77 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1998 | 280 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 1997 | 220 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 39 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2015 | 27 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2015 | 36 | 0.030 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 1994 | 2 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1997 | 241 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 1996 | 159 | 0.030 |
Why?
|
| HIV-1 | 1 | 1995 | 73 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1994 | 39 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 222 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2014 | 18 | 0.030 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 1994 | 2 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 1994 | 7 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1994 | 33 | 0.030 |
Why?
|
| Dentists | 1 | 1994 | 14 | 0.030 |
Why?
|
| Program Evaluation | 2 | 2006 | 222 | 0.030 |
Why?
|
| Trust | 1 | 2013 | 30 | 0.030 |
Why?
|
| Biomarkers | 1 | 1994 | 312 | 0.030 |
Why?
|
| Counseling | 1 | 1994 | 187 | 0.030 |
Why?
|
| Legislation, Medical | 1 | 1993 | 5 | 0.030 |
Why?
|
| Health Policy | 1 | 1994 | 118 | 0.030 |
Why?
|
| Self Concept | 1 | 1993 | 39 | 0.030 |
Why?
|
| Physicians | 1 | 1994 | 135 | 0.030 |
Why?
|
| Uncertainty | 1 | 1992 | 7 | 0.030 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1993 | 54 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 1992 | 154 | 0.020 |
Why?
|
| Suction | 1 | 2011 | 1 | 0.020 |
Why?
|
| Hand | 1 | 2011 | 3 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 129 | 0.020 |
Why?
|
| Milk, Human | 1 | 2011 | 7 | 0.020 |
Why?
|
| Safety Management | 1 | 2011 | 13 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 93 | 0.020 |
Why?
|
| Lactation | 1 | 2011 | 53 | 0.020 |
Why?
|
| Plant Bark | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cost Control | 1 | 1990 | 17 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 9 | 0.020 |
Why?
|
| Ethics Committees, Clinical | 1 | 1989 | 1 | 0.020 |
Why?
|
| Information Systems | 1 | 2009 | 19 | 0.020 |
Why?
|
| Mandatory Programs | 1 | 1989 | 6 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 1989 | 14 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 1989 | 10 | 0.020 |
Why?
|
| Fruit | 1 | 2009 | 79 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 85 | 0.020 |
Why?
|
| Physical Stimulation | 1 | 2009 | 1 | 0.020 |
Why?
|
| Acupuncture Points | 1 | 2009 | 3 | 0.020 |
Why?
|
| Needles | 1 | 2009 | 3 | 0.020 |
Why?
|
| Immunization Programs | 1 | 2009 | 65 | 0.020 |
Why?
|
| Condoms | 3 | 1994 | 33 | 0.020 |
Why?
|
| Epidemiology | 1 | 2006 | 5 | 0.020 |
Why?
|
| Authorship | 1 | 2006 | 5 | 0.020 |
Why?
|
| Mentors | 1 | 2006 | 7 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 146 | 0.020 |
Why?
|
| Homosexuality, Male | 2 | 1995 | 38 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 179 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 204 | 0.010 |
Why?
|
| Federal Government | 2 | 1994 | 12 | 0.010 |
Why?
|
| Consensus | 1 | 2004 | 40 | 0.010 |
Why?
|
| Illinois | 1 | 2003 | 8 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 9 | 0.010 |
Why?
|
| Decision Support Techniques | 2 | 1994 | 88 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 25 | 0.010 |
Why?
|
| Inpatients | 2 | 1994 | 81 | 0.010 |
Why?
|
| Sexual Partners | 2 | 1993 | 38 | 0.010 |
Why?
|
| Helicobacter Infections | 1 | 2000 | 22 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2000 | 29 | 0.010 |
Why?
|
| Personality Assessment | 1 | 1996 | 15 | 0.010 |
Why?
|
| Social Environment | 1 | 1995 | 87 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 17 | 0.010 |
Why?
|
| Personnel, Hospital | 1 | 1994 | 9 | 0.010 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 1994 | 32 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1994 | 12 | 0.010 |
Why?
|
| HIV Seroprevalence | 1 | 1994 | 2 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1995 | 304 | 0.010 |
Why?
|
| Disclosure | 1 | 1994 | 17 | 0.010 |
Why?
|
| Self Disclosure | 1 | 1993 | 22 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1995 | 361 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 1996 | 420 | 0.010 |
Why?
|